PARTICULARS TO APPEAR ON THE OUTER PACKAGE (Carton)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vetmedin 5 mg hard capsules

2. STATEMENT OF ACTIVE SUBSTANCES

Each capsule contains:

Active substance:
Pimobendan 5.00 mg

3. PACKAGE SIZE

100 capsules

4. TARGET SPECIES

Dog

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.
Store in a dry place.
Keep the container tightly closed.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH

14. MARKETING AUTHORISATION NUMBERS

Vm 61700/5010
Vm 61700/3010

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE (Label)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vetmedin 5 mg capsules.

2. STATEMENT OF ACTIVE SUBSTANCES

Each capsule contains:

Active substance:
Pimobendan 5.00 mg

3. TARGET SPECIES

Dog

4. ROUTES OF ADMINISTRATION

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

6. EXPIRY DATE

Exp. {mm/yyyy}

7. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.
Store in a dry place.
Keep the container tightly closed.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH

9. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Vetmedin 5 mg hard capsules

2. Composition

Each capsule contains:

Active substance:
Pimobendan 5.00 mg
Hard capsule, orange/white in colour

3. Target species

Dog

4. Indications for use

Vetmedin belongs to a group of medicines which help the weakened heart to pump blood around the body.
How Vetmedin Helps Your Dog:
In a range of heart conditions, for example where the heart valves are leaky or where the heart is enlarged, blood is less efficiently pumped around the body. Vetmedin helps the circulation of blood by strengthening the heart muscle. It should only be administered to dogs with heart problems.

5. Contraindications

Before Giving Vetmedin
Tell your Veterinary Surgeon if:
– Your dog is pregnant or has recently had puppies
– Your dog is taking any other drug
– Your dog has reacted badly to previous related medication

If in doubt, ask your Veterinary Surgeon.

Information for the Veterinary Surgeon:

Contra-indications and warning

Only for use in dogs with cardiac insufficiency. When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend

life expectancy in treated dogs. Vetmedin capsules should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (eg aortic stenosis). Pimobendan, a benzimidazolepyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties. Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity. The combined evidence from cell culture, laboratory animal and small studies in the target species suggests that the combination of the specific PD properties of pimobendan may reduce the progression of myocardial damage in dogs with MVD and DCM when used together with other standard therapy. A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed. The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the b-antagonist propranolol. In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In experiments with rats it has been shown that pimobendan is excreted into milk. In cases of mild congestive heart failure, a daily dosage at the lower end of the dose range may be adequate. If, however, a clear response is not observable within one week, the dosage should be increased. Following oral administration of Vetmedin capsules, the absolute bioavailability of the active principle is 60-63%.
Bioavailability is considerably reduced when pimobendan is administered with food shortly thereafter. Hence it is recommended to be given 1 hour before feeding. The mean plasma binding is 93%. The plasma elimination half-life is approximately 30 minutes and the mean metabolite elimination half-life is approximately 2 hours. Almost the entire dose is eliminated via the faeces. To be supplied only on veterinary prescription.

6. Special warnings

Special warnings:
None

Special precautions for safe use in the target species:
This veterinary medical product should only be used in dogs with cardiac insufficiency. Do not exceed the recommended dose.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In the event of accidental ingestion, seek medical advice and show this leaflet or the label to the doctor.

Operator warnings: In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:
Not applicable.

Pregnancy and lactation:
No information is available on the safety in pregnant and lactating bitches.

Interaction with other medicinal products and other forms of interaction:>
In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected.

Overdose:
In case of overdose symptomatic treatment should be initiated.

7. Adverse events

Dog:

Rare (1 to 10 animals / 10,000 animals treated):	A moderate positive chronotropic effect and vomiting[1] Transient diarrhoea, Anorexia, Lethargy

[1]These effects are dose-dependent and can be avoided by reducing the dose in these cases.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

The usual recommended dosage is shown in the table below. The total daily dose should be divided into two equal administrations; one half should be given in the morning and the other half approximately 12 hours later. Vetmedin should be given by mouth (approximately 1 hour before feeding). Your vet may give alternative advice in special circumstances as the minimum effective dose may vary in individual animals.

Daily Pimobendan Dosage: 0.2 – 0.6 mg/kg							
Body Weight (kg)	**Daily Dosage (mg)**	**No. of capsules per administration**					
		Morning 5.0 mg			**Evening 5.0 mg**		
< 10	2.5	1	-	-	1	-	-
10-20	5	-	1	-	-	1	-
21-40	10	-	-	1	-	-	1
41-60	20	-	-	2	-	-	2
> 60	30	-	-	3	-	-	3

9. Advice on correct administration

Vetmedin Capsules may be combined with a diuretic treatment such as frusemide. Do not administer other medication without first consulting your veterinary surgeon. Do not give more than the recommended dosage. Determine the bodyweight accurately before treatment to ensure correct dosage. In the event of overdosage consult a veterinary surgeon immediately.

10. Withdrawal periods

11. Special storage precautions

Keep out of the sight and reach of children.
Do not store above 25 °C.
Store in tightly closed original container.
Store in a dry place.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medical product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 61700/5010
Vm 61700/3010

100 capsules

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Manufacturer responsible for batch release:
Klocke Pharma Service GmbH
D 77767 Appenweier
Germany

17. Other information

POM-V

Gavin Hall
Approved: 02 December 2025